Identification and isolation of antibodies directly from human B cells

BliNK Biomedical's powerful B cell technology enables the selection and isolation of specific antibody producing cells for difficult targets from B cells of many species, such as man, mouse, rabbit, dog, etc. This cutting-edge technology, based on the validated platforms (ISAAC and VIVA|Screen), constitute a highly efficient and deep mining process and provides an unprecedented capability to identify very rare antibody-secreting cells from human and other species. This unique capability represents a major advantage compared to other technologies and enables the identification of unique therapeutic antibodies.

Our headquarters are in Marseille (France).